US2019298839A1PendingUtilityA1

Method and composition for alleviating or preventing ischemic tissue damage

67
Individually held — no corporate assignee on recordPriority: Mar 26, 2009Filed: Jun 19, 2019Published: Oct 3, 2019
Est. expiryMar 26, 2029(~2.7 yrs left)· nominal 20-yr term from priority
Inventors:Jeffrey E. Thomas
A61K 9/0085A61K 33/26A61K 47/46A61K 31/198A61K 47/26A61K 31/21A61K 9/0019
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition for increasing collateral circulation includes a pharmaceutically acceptable synthetic cerebrospinal fluid. The pharmaceutically acceptable synthetic cerebrospinal fluid includes a density altering agent. The synthetic cerebrospinal fluid has a density different from a density of naturally-occurring cerebrospinal fluid. The density-altering agent includes about 5 to about 8.25 percent by volume of dextrose. The composition also includes a vasodilator.

Claims

exact text as granted — not AI-modified
1 . A composition for increasing collateral circulation, comprising:
 a pharmaceutically acceptable synthetic cerebrospinal fluid comprising a density altering agent, wherein the synthetic cerebrospinal fluid has a density different from a density of naturally-occurring cerebrospinal fluid; and wherein the density-altering agent comprises about 5 to about 8.25 percent by volume of dextrose; and   a vasodilator.   
     
     
         2 . The composition of  claim 1 , wherein the vasodilator is selected from at least one member of the group consisting of nitroglycerine, nitroprusside, a nitroprusside salt, sodium nitroprusside, arginine, and mixtures thereof. 
     
     
         3 . The composition of  claim 1 , wherein the vasodilator is present in amounts from about 0.25 mg/ml to about 4 mg/ml. 
     
     
         4 . The composition of  claim 1 , wherein the composition has an acidic pH. 
     
     
         5 . The composition of  claim 1 , comprising a neutroprotectant. 
     
     
         6 . The composition of  claim 5 , wherein the neutroprotectant comprises spin trap agents, free radical scavengers, anti-inflammatory agents, or a combination thereof. 
     
     
         7 . The composition of  claim 1 , wherein the density of the synthetic cerebrospinal fluid is less than the density of the naturally-occurring cerebrospinal fluid. 
     
     
         8 . The composition of  claim 1 , wherein the density of the synthetic cerebrospinal fluid is greater than the density of the naturally-occurring cerebrospinal fluid. 
     
     
         9 . A method for increasing collateral circulation in a patient comprising:
 providing a pharmaceutically acceptable synthetic cerebrospinal fluid comprising a density altering agent, wherein the synthetic cerebrospinal fluid has a density different from a density of naturally-occurring cerebrospinal fluid; and wherein the density-altering agent comprises about 5 to about 8.25 percent by volume of dextrose;   mixing a vasodilator with the synthetic cerebrospinal fluid; and   administering the resulting mixture to a patient.   
     
     
         10 . The method of  claim 9 , comprising administering the mixture to an intrathecal space of the patient through an intraventricular route to the patient's brain. 
     
     
         11 . The method of  claim 10 , comprising administering the mixture to an intrathecal space of the patient using a ventriculostomy catheter. 
     
     
         12 . The method of  claim 9 , comprising administering the composition to an intrathecal space of the patient through a needle access to the cisterna magna of the patient. 
     
     
         13 . The method of  claim 9 , comprising placing the patient in a head-down position. 
     
     
         14 . The composition of  claim 9 , wherein the vasodilator is selected from at least one member of the group consisting of nitroglycerine, nitroprusside, a nitroprusside salt, sodium nitroprusside, arginine, and mixtures thereof. 
     
     
         15 . A method for treating or inhibiting ischemic damage comprising:
 providing a pharmaceutically acceptable synthetic cerebrospinal fluid having a density different from a density of naturally-occurring cerebrospinal fluid, wherein the synthetic cerebrospinal fluid comprises a density-altering agent comprising about 5 to about 8.25 percent by volume of dextrose;   mixing a vasodilator and neutroprotectant, with the synthetic cerebrospinal fluid to form a mixture; and   administering the mixture to a patient.   
     
     
         16 . The method of  claim 15 , comprising administering the mixture to an intrathecal space of the patient through an intraventricular route to the patient's brain. 
     
     
         17 . The method of  claim 16 , comprising administering the mixture to an intrathecal space of the patient using a ventriculostomy catheter. 
     
     
         18 . The method of  claim 15 , comprising administering the mixture to an intrathecal space of the patient through a needle access to the cisterna magna of the patient. 
     
     
         19 . The method of  claim 15 , comprising placing the patient in a head-down position. 
     
     
         20 . The composition of  claim 15 , comprising mixing the vasodilator present in amounts from about 0.25 mg/ml to about 4 mg/ml.

Join the waitlist — get patent alerts

Track US2019298839A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.